Novartis

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Ad hoc announcement pursuant to Art. 53 LR

Novartis plans to petition the U.S. Supreme Court to uphold validity of the Gilenya® (fingolimod) dosing regimen patent

Novartis (NVS) generic unit Sandoz announces that ROSALIA study for its proposed biosimilar of Prolia (denosumab) meets primary endpoints.

Novartis (NVS) Unit Posts Positive Results on Prolia Biosimilar

British American Tobacco

The market is down 10% in a month and the blue-chip economist consensus thinks we have about 20% more to fall before we hit the final bear market bottom. Glorious 10-year profits are coming for anyone who can stay safe, sane, and disciplined through the final months of volatility. This is where high-yield, low-volatility defensive blue-chip bargains can help.

2 High-Yield Sleep Well At Night Dividend Aristocrats For This Volatile Market

AbbVie

AstraZeneca

Merck

Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, AbbVie (ABBV), Novartis (NVS), Merck (MRK) and AstraZeneca (AZN) are worth retaining in your portfolio.

4 Large Drug Stocks to Watch as Fundamentals Stay Strong

Novartis is the subject of an investigation by the Swiss competition commission into patent use, the Swiss pharmaceutical company said on Thursday.

Novartis says it is subject of Swiss competition probe

Basel, September 15, 2022 — Novartis today confirms that it has been contacted by the Swiss Competition Commission (COMCO) which has initiated an investigation, in collaboration with the European Commission, into the assertion of a patent in the broader field of dermatology treatments. In connection with this investigation, COMCO representatives visited the company headquarters in Basel.

Novartis statement regarding competition authority investigation into assertion of a patent

The Swiss competition commission (COMCO) has opened an investigation of Novartis over possible unlawful use of a patent to reduce competitive pressure, the Swiss drugmaker confirmed on Thursday.

Swiss competition watchdog probes Novartis over patent use

Sanofi

Investors might want to take a look at Euroapi S.A. ( XPAR:EAPI , Financial), a Paris-based firm that is a spin-off of Sanofi ( SNY , Financial).

Results for Sanofi Spin-Off Good Omen for Sandoz Generics

Bank of Montreal

Intel

Manulife Financial

Verizon

A difficult economic environment such as the one we are currently experiencing provides the best time to find good investments at a discount, because paying the right price has a significant influence on long-term investment returns. The current market negativity has resulted in many high-quality companies' market values being unfairly punished by indiscriminate selling, creating material discounts to intrinsic value.

5 Good Companies Selling for a Pittance

Basel, September 10, 2022 — Novartis announced the results from two pivotal, Phase III studies (SUNSHINE and SUNRISE), in which Cosentyx® (secukinumab) demonstrated rapid and sustained relief from the common clinical signs and symptoms of moderate-to-severe hidradenitis suppurativa (HS) with a favorable safety profile5,6. The data were presented as a late-breaking abstract at the 31st European Academy of Dermatology and Venereology (EADV) Congress1.

Novartis Cosentyx® shows clinically meaningful symptom improvements in patients with hidradenitis suppurativa in pivotal Phase III trials

Pharmaceuticals company Novartis plans to close a Sandoz generics plant in Wilson, North Carolina, around the end of 2023, it said on Friday, citing inability to use the U.S. site to full capacity.

Novartis plans to close a Sandoz plant in North Carolina

Basel, September 9, 2022 — Novartis today announced results from a new pooled exploratory analysis across the entire MONALEESA Phase III program, confirming nearly one year of additional overall survival (OS) benefit in a subgroup of patients with aggressive forms of hormone receptor-positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer (aBC)1. This subgroup analysis found that patients with visceral metastases—including liver metastases and multiple metastatic sites, which are typically associated with a poor prognosis—who were treated with Kisqali® (ribociclib) plus endocrine therapy in the first-line setting, achieved a median OS of 62.7 months compared to 52.1 months for those treated with endocrine therapy alone (HR=0.79; 95% CI: 0.65-0.97)1. Data from this analysis will be presented at the European Society of Medical Oncology (ESMO) Congress in Paris, France.

Novartis Kisqali® adds one more year of survival benefit for broadest set of patients, including those with aggressive HR+/HER2- advanced breast cancer

Basel, September 2, 2022 — Novartis today announced it will showcase data from its leading immunology portfolio and emerging pipeline at the upcoming 31st European Academy of Dermatology and Venereology (EADV) Congress and the 15th International Symposium on Sjögren's Syndrome (ISSS), both occurring September 7–10, 2022. A total of 37 abstracts will be shared across both meetings, spanning hidradenitis suppurativa (HS), chronic spontaneous urticaria (CSU), Sjögren's syndrome, axial spondyloarthritis, and psoriasis.

Novartis highlights depth of immunology pipeline with novel data at key upcoming international congresses

GlaxoSmithKline

Morgan Stanley

Novavax

Pfizer

It started out relatively small, or as small as a recall of one of the first drugs to top $1 billion in annual sales can be. In September 2019, individual companies began recalling popular heartburn medication Zantac.

This Overlooked Danger Could Tank Big Pharma Stocks

Novartis appointed Merck executive Fiona Marshall as president of the Novartis Institutes for Biomedical Research to replace Jay Bradner, who is stepping down as research head at the Swiss drugmaker, it said on Thursday.

Novartis taps MSD exec Marshall to replace Bradner as research head

Basel, September 1, 2022 — Novartis today announced that James (Jay) E. Bradner, M.D., will step down from the Executive Committee of Novartis (ECN), effective October 31st after seven years leading research at Novartis. Fiona H. Marshall, Ph.D., currently Senior Vice President and Global Head of Discovery Sciences, Preclinical Development and Translational Medicine at MSD (Merck & Co., Inc in USA), has been appointed as President of the Novartis Institutes for BioMedical Research (NIBR), effective November 1st, 2022 reporting to Vas Narasimhan, M.D., CEO of Novartis. Dr. Marshall will become a member of the ECN.

Novartis appoints Fiona Marshall, Ph.D., President of the Novartis Institutes for BioMedical Research as Jay Bradner, M.D.

Novartis (NVS) strengthens its oncology portfolio with EC approval for its chronic myeloid leukemia drug, Scemblix.

Novartis (NVS) Chronic Myeloid Leukemia Drug Approved by EC

Basel, August 30, 2022 — Novartis will showcase new data from across its oncology portfolio at the European Society for Medical Oncology (ESMO) Congress 2022 with over 35 accepted abstracts from Novartis-sponsored and investigator-initiated trials including new data in advanced breast cancer and metastatic castration-resistant prostate cancer.

Novartis presents new data in breast and prostate cancer at ESMO

These reports, excerpted and edited by Barron's, were issued recently by investment and research firms. The reports are a sampling of analysts' thinking; they should not be considered the views or recommendations of Barron's.

Novartis Looks Appealing, Based on Strong Drug Pipeline and Planned Sandoz Spinoff

Novartis CEO Vas Narasimhan could struggle to woo investors to the listing of generics drugs business Sandoz, as weaker drug prices and jittery financial markets present one of his biggest challenges in the years-long overhaul of the Swiss drugmaker.

Analysis-Novartis CEO may struggle to rally investors to Sandoz spin-off

In the event of a recession, this is a stock that can potentially do better than the market, and so far it has already proven that. Novartis' dividend currently has a dividend yield (FWD) of 3.98%, much higher than the industry average of 2.28%. What's more, this dividend is absolutely sustainable.

Novartis: Undervalued And Trustworthy

Novartis (NVS) is set to spin off Sandoz into a new publicly traded standalone company to focus better on its core pharmaceutical business.

Novartis (NVS) Plans to Spin Off Generics Business Sandoz

Novartis AG is planning to spin off its generics-and-biosimilars division Sandoz and list it as a standalone company in Switzerland, a move that will enable Novartis to focus on innovative medicines.

Novartis to spin off, list Sandoz business

Novartis said on Thursday it would spin off Sandoz and list it on the Swiss stock exchange to create the No.1 European generics company.

Novartis to spin off Sandoz, list it in Zurich

Sandoz strategic review concludes that a separation of Sandoz by way of a 100% spin-off is in the best interest of shareholders, creating the #1 European generics company and a global leader in biosimilars, and a more focused Novartis

News for Novartis Stock (NVS)